Clinical Trials in Oncology

Jacob Fleming Conferences16-17 September 2010, Budapest, Hungary.
Cancer is the fastest growing healthcare priority within the pharmaceutical industry worldwide, with rising research, treatment and commercial importance. Carefully designed and efficiently conducted clinical trial can deliver new oncology drugs and diagnostics to the marketplace. There is a number of challenges in this area which remain; specifically regarding patient recruitment and regulatory issues.

Attend to explore effective patient recruitment and enrollment strategies and understand regulatory considerations surrounding clinical trials in oncology. Leading Pharma companies will share first hand experience with adaptive trial designs and case studies on conducting clinical trials in emerging markets in CEE, APAC and India.

At this conference, you will have the chance to meet true market leaders, top speakers and real experts from the pharmaceutical industry as well as from the oncology-focused institutions and organizations. Do not miss the opportunity to gain new knowledge and join us at this event of the year.

Key speakers:

  • Vice President, Chief Clinical Officer, Teva, Israel
  • Global Clinical Operations Head Oncology, Johnson & Johnson, UK
  • Chief Medical Officer, Kiadis Pharma, The Netherlands
  • Group Head Clinical Project Management, Pfizer, Germany
  • Clinical Trials Consultant to MHRA, UK
  • Clinical Trial Head, Novartis, Switzerland
  • CRUK Professor of Translational Cancer Research, University of Glasgow, UK
  • Director Clinical Research Internal Medicine Early Stage Development, Merck Sharp & Dohme, The Netherlands
  • Principal Clinical Development Scientist, GlaxoSmithKline, UK
  • Executive Director, Oncology Global Development and Medical Affairs, Bristol Myers Squibb, France
  • Group Leader Global Clinical Development Unit Oncology, MerckSerono, Germany

Key topics:

  • Recruitment and enrollment in clinical trials. Expectations and reality.
  • Current regulatory situation in relation to clinical trials in the EU
  • Biomarkers as valuable decision making tools in clinical drug development
  • How are Pharma companies implementing and managing adaptive clinical trial
  • Challenges and opportunities of conducting clinical trials in Emerging Markets

Who should attend:
Vice presidents, Global heads, Heads, Directors, Senior managers, Managers within pharmaceutical companies and oncology-focused institutions and organizations responsible for: Oncology, Clinical research and Development, Clinical trials, Clinical operations, Medical affairs, Drug development and research, Biomarkers, Imaging.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/clinical-trials-in-oncology

About the Jacob Fleming Conferences
Jacob Fleming Conferences have always been carefully designed to provide key strategic business information and the best networking opportunities for the participants. This young, dynamically growing company provides events for specialized industries including Finance, Life Science, Telecommunications, Chemical, and cross industry sectors. Extensive research, targeted speaker selection and top class venues provide a unique incentive and exceptional opportunities for the executives and experts participating in Jacob Fleming conferences. For more information, visit www.jacobfleming.com.

Most Popular Now

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...